drug
EVEROLIMUS
Marketedupdated 3mo agoby Novugen Pharma (Malaysia) Sdn Bhd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugeverolimus SR36 co-mentions · 24 sources
- drugeverolimus ODT36 co-mentions · 24 sources
- drugZortress36 co-mentions · 24 sources
- tagApproval16 co-mentions · 8 sources
- tagAdCom15 co-mentions · 11 sources
- tagPMA Approval15 co-mentions · 11 sources
- tagSmall Molecule8 co-mentions · 8 sources
- companyPar Pharmaceutical Inc5 co-mentions · 5 sources
all catalysts(6)
approval · 6
Mar 5, 2021
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Jun 22, 2023
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Jun 22, 2023
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Jun 22, 2023
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Jan 9, 2026
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Mar 6, 2026
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Trials studying EVEROLIMUS
- phase3Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- phase2A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- phase2A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
- —REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia
- phase2Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
- phase4A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
- phase2Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- phase2Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 1, 2028
~1.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Jul 1, 2028method-of-use (U-1681)US 90062241.9y
- Jul 1, 2028method-of-use (U-1681)US 90062241.9y
- Jul 1, 2028method-of-use (U-1681)US 90062241.9y
- Jul 1, 2028method-of-use (U-1681)US 90062241.9y
- May 1, 2026patentUS 8410131*PED
- May 1, 2026patentUS 8410131*PED
- May 1, 2026patentUS 8410131*PED
- May 1, 2026patentUS 8410131*PED
- Nov 1, 2025method-of-use (U-1368)US 8410131
- Nov 1, 2025method-of-use (U-1368)US 8410131
- Nov 1, 2025method-of-use (U-1368)US 8410131
- Nov 1, 2025method-of-use (U-1368)US 8410131
News(3)
- FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issuesITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns.biospace · 3d ago
- STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatmentThe FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.stat · 4d ago
- Opinion: I’m a heart transplant recipient. I’m haunted by ‘ghost approval’ for medication I need to survive“On paper, I have insurance coverage. In real life, I don’t have access. That’s what I call ‘ghost approval,’” writes patient advocate Payton Herres.stat · 2mo ago
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that